https://www.biospace.com/lung-diease Lung diease en-US Tue, 08 Sep 2026 12:46:08 GMT https://www.biospace.com/press-releases/roivant-announces-positive-results-from-phocus-study-of-mosliciguat-in-patients-with-pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-and-unveils-ongoing-phase-3-phrontier-study Tue, 08 Sep 2026 12:46:08 GMT https://www.biospace.com/press-releases/roivant-announces-positive-results-from-phocus-study-of-mosliciguat-in-patients-with-pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-and-unveils-ongoing-phase-3-phrontier-study https://www.biospace.com/press-releases/pulmovant-announces-positive-results-from-phocus-study-of-mosliciguat-in-patients-with-pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-and-unveils-ongoing-phase-3-phrontier-study Tue, 08 Sep 2026 12:44:45 GMT https://www.biospace.com/press-releases/pulmovant-announces-positive-results-from-phocus-study-of-mosliciguat-in-patients-with-pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-and-unveils-ongoing-phase-3-phrontier-study https://www.biospace.com/press-releases/pulmovant-to-present-topline-results-from-the-phase-2-phocus-study-of-mosliciguat-in-patients-with-pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-at-the-ers-congress-2026-on-tuesday-september-8-2026 Mon, 07 Sep 2026 00:57:46 GMT https://www.biospace.com/press-releases/pulmovant-to-present-topline-results-from-the-phase-2-phocus-study-of-mosliciguat-in-patients-with-pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-at-the-ers-congress-2026-on-tuesday-september-8-2026 https://www.biospace.com/press-releases/roivant-to-present-topline-results-from-the-phase-2-phocus-study-of-mosliciguat-in-patients-with-pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-at-the-ers-congress-2026-on-tuesday-september-8-2026-and-host-investor-call Mon, 07 Sep 2026 00:57:21 GMT https://www.biospace.com/press-releases/roivant-to-present-topline-results-from-the-phase-2-phocus-study-of-mosliciguat-in-patients-with-pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-at-the-ers-congress-2026-on-tuesday-september-8-2026-and-host-investor-call https://www.biospace.com/press-releases/sentynl-therapeutics-and-mereo-biopharma-announce-option-and-license-agreement-for-alvelestat-in-alpha-1-antitrypsin-deficiency-associated-lung-disease-aatd-ld Tue, 11 Aug 2026 13:39:09 GMT https://www.biospace.com/press-releases/sentynl-therapeutics-and-mereo-biopharma-announce-option-and-license-agreement-for-alvelestat-in-alpha-1-antitrypsin-deficiency-associated-lung-disease-aatd-ld https://www.biospace.com/press-releases/mereo-biopharma-and-sentynl-therapeutics-announce-option-and-license-agreement-for-alvelestat-in-alpha-1-antitrypsin-deficiency-associated-lung-disease-aatd-ld Tue, 11 Aug 2026 13:18:36 GMT https://www.biospace.com/press-releases/mereo-biopharma-and-sentynl-therapeutics-announce-option-and-license-agreement-for-alvelestat-in-alpha-1-antitrypsin-deficiency-associated-lung-disease-aatd-ld https://www.biospace.com/press-releases/mannkind-announces-ralinepag-dry-powder-inhalation-dpi-program-to-be-pursued-for-pulmonary-hypertension-and-fibrotic-lung-diseases Wed, 06 May 2026 11:48:47 GMT https://www.biospace.com/press-releases/mannkind-announces-ralinepag-dry-powder-inhalation-dpi-program-to-be-pursued-for-pulmonary-hypertension-and-fibrotic-lung-diseases https://www.biospace.com/press-releases/humanetics-corporation-announces-investigator-initiated-phase-2-trial-in-patients-with-non-small-cell-lung-cancer-and-underlying-interstitial-lung-disease Wed, 01 Apr 2026 05:28:38 GMT https://www.biospace.com/press-releases/humanetics-corporation-announces-investigator-initiated-phase-2-trial-in-patients-with-non-small-cell-lung-cancer-and-underlying-interstitial-lung-disease https://www.biospace.com/press-releases/an2-therapeutics-announces-initiation-of-phase-2-investigator-initiated-clinical-trial-of-epetraborole-for-mycobacterium-abscessus-complex-lung-disease Tue, 31 Mar 2026 13:18:04 GMT https://www.biospace.com/press-releases/an2-therapeutics-announces-initiation-of-phase-2-investigator-initiated-clinical-trial-of-epetraborole-for-mycobacterium-abscessus-complex-lung-disease https://www.biospace.com/press-releases/pulmonary-fibrosis-foundation-expands-national-care-network-strengthening-access-to-expert-lung-disease-care Fri, 06 Mar 2026 01:11:22 GMT https://www.biospace.com/press-releases/pulmonary-fibrosis-foundation-expands-national-care-network-strengthening-access-to-expert-lung-disease-care https://www.biospace.com/press-releases/altesa-biosciences-closes-oversubscribed-75-million-series-b-financing-to-transform-treatment-of-chronic-lung-diseases Thu, 19 Feb 2026 13:25:13 GMT https://www.biospace.com/press-releases/altesa-biosciences-closes-oversubscribed-75-million-series-b-financing-to-transform-treatment-of-chronic-lung-diseases https://www.biospace.com/press-releases/pulmovant-announces-completion-of-enrollment-in-the-phase-2-phocus-study-of-mosliciguat-in-patients-with-pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild Mon, 09 Feb 2026 00:28:40 GMT https://www.biospace.com/press-releases/pulmovant-announces-completion-of-enrollment-in-the-phase-2-phocus-study-of-mosliciguat-in-patients-with-pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild https://www.biospace.com/press-releases/an2-therapeutics-announces-fda-clearance-to-proceed-with-90-patient-investigator-initiated-trial-iit-of-epetraborole-in-patients-with-m-abscessus-lung-disease Mon, 12 Jan 2026 15:18:35 GMT https://www.biospace.com/press-releases/an2-therapeutics-announces-fda-clearance-to-proceed-with-90-patient-investigator-initiated-trial-iit-of-epetraborole-in-patients-with-m-abscessus-lung-disease